Todos Medical makes progress with TolloTest enrollment as its Tollovir dietary supplement also receives interest

Todos Medical Ltd (OTCQB:TOMDF) has revealed that it continues to make progress with enrollment of its Phase 2 clinical trial to treat hospitalized coronavirus (COVID-19) patients in Israel, with its TolloTest biomarker being used for the first time as a surrogate biomarker to monitor patient response to treatment. In a second-quarter 2021 corporate update, the medical diagnostics and related solutions company also said its partners at NLC Pharma have identified an anti-inflammatory mechanism of action for its Tollovir dietary supplement to complement its 3CL protease inhibiting mechanism. Tollovid, a mix of botanical extracts, is being targeted to support healthy immune function against circulating coronaviruses.  READ: Todos Medical receives US FDA certificate of free sale for its new five-day Tollovid dosing regimen The company said the dual mechanism of action helps to explain the significant reduction in symptoms and the biomarker C Reactive Protein (CRP) that was documented in the earliest clinical COVID-19 data sets produced in Israel, which could not be explained by a reduction in viral load alone likely caused by Tollovir’s 3CL protease inhibiting mechanism. Todos Medical said Tollovir may ultimately represent a new standard of care in the treatment and management of COVID-19 patients, and it is working to make certain its clinical development execution will lead to the creation of clinical data that will be extremely valuable for regulators seeking to approve the product’s use, as well as potential partners who may become further interested in the program as additional clinical and scientific data emerges. “In light of the emerging Delta variant circulating widely in the US, there is now a clear need for novel COVID-19 antiviral therapies to protect the unvaccinated and those for whom authorized vaccines do not confer immunity, which includes a large portion of the elderly and those taking immune suppressants, against COVID-19 infection,” Todos Medical CEO Gerald E. Commissiong said in a statement. “The Biden administration recently underscored this need by pledging to invest $3.2 billion into research for COVID-19 antiviral therapies, similar to the US government’s investments into COVID-19 vaccines in 2020 at the beginning of the pandemic. “We believe this government recognition of the need for antivirals will provide a significant tailwind for the development of our Tollovir antiviral that is currently undergoing a Phase 2 clinical trial in Israel with plans progressing rapidly to expand the clinical development program to India," he added. Todos Medical said it has seen interest from several potential international distribution partners for Tollovid and expects to build a significant international distribution footprint in the second half of 2021 as it begins its initial roll-out of the dietary supplement. The company said it will seek distribution partnerships in jurisdictions where high-value dietary supplements are distributed by reputable pharmacies and other high-end wellness stores that can engage with consumers directly on the value and underlying science of their products. In the US, it will focus on a marketing campaign to dramatically expand awareness of Tollovid for consumers and distribution partners who are looking for products to further support immune function. Contact the author at stephen.gunnion@proactiveinvestors.com